{"id":"W4214695698","doi":"10.1007/s12325-022-02068-7","title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; H. Lundbeck A/S; Biogen; Celgene; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Sanofi; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Medicine; Glatiramer acetate; Tolerability; Discontinuation; Dimethyl fumarate; Adverse effect; Multiple sclerosis; Internal medicine; Natalizumab; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007213303,0.0003403935,0.0006420073,0.00009294567,0.0004163844,0.00006343409,0.0002817331,0.00002879958,0.0002140462],"category_scores_gemma":[0.0003373862,0.0001689454,0.0000596936,0.0002741646,0.000160757,0.0002267849,0.0001850811,0.0006146476,0.000003266314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001114447,"about_ca_system_score_gemma":0.00003679542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000641077,"about_ca_topic_score_gemma":0.001156947,"domain_scores_codex":[0.9971973,0.0004845194,0.0004826592,0.0006744438,0.0007691468,0.0003918829],"domain_scores_gemma":[0.9953161,0.003700763,0.0001820665,0.0006690699,0.00005380178,0.00007817727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1481396,0.002150708,0.3104295,0.000006487802,0.0007321211,0.0001458445,0.06684733,0.0001238461,0.002216459,0.000003134487,0.00003562439,0.4691693],"study_design_scores_gemma":[0.06358311,0.003734858,0.904415,0.0002055717,0.00003831593,0.000001360173,0.01307413,0.0001560227,0.0002214749,0.00005653234,0.01425044,0.0002631767],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819528,0.01325764,0.00003239355,0.001932013,0.0001319311,0.002321486,0.0002155687,0.00006336199,0.00009276724],"genre_scores_gemma":[0.9891925,0.008606291,0.0005362693,0.0007817298,0.0001302951,0.0005277201,0.00003073988,0.00004651337,0.0001478944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5939855,"threshold_uncertainty_score":0.6889395,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03422665416530311,"score_gpt":0.3606155336236517,"score_spread":0.3263888794583485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}